Navigation Links
Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer

NEW HAVEN, Conn., Sept. 4 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of acute care antibiotic-resistant infections, announced today that Thomas R. Kassberg has joined the company as Chief Business Officer. In his new role, Mr. Kassberg will lead the company's business development activities.

Mr. Kassberg, age 49, joins Rib-X from Proteolix, Inc., where he served as Executive Vice President of Corporate Development, overseeing business development, corporate strategic planning and legal affairs. Prior to Proteolix, Mr. Kassberg had over a decade of experience in leadership roles in business development in the biotechnology industry, holding positions at InterMune, Inc., Plexxikon, Inc. (a company he co-founded), and SUGEN, Inc.

Mr. Kassberg began his career at Bristol-Myers Squibb where he held a variety of positions in finance, product and market analysis, and sales. Mr. Kassberg received his M.B.A. from the Kellogg Graduate School of Management at Northwestern University and his B.A. from Gustavus Adolphus College in Minnesota.

"Tom joins Rib-X at a particularly important time in our growth, as we explore potential partnership opportunities for our lead antibiotic compounds, delafloxacin and radezolid, which have successfully completed multiple Phase 2 clinical trials," said Susan Froshauer, PhD, President and Chief Executive Officer of Rib-X Pharmaceuticals. "His business development experience and background are an ideal fit for what we need at this stage in our maturation."

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. In addition to Rx-04, Rib-X has successfully completed Phase 2 trials with delafloxacin (RX-3341), a broad spectrum fluoroquinolone with potent activity against quinolone resistant Gram-positive bacteria including MRSA. Radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X, as an oral/IV agent for treatment of serious Gram-positive infections has completed two Phase 2 trials and the Rx-02 discovery program which is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococcus pneumoniae and S. pyogenes. Both delafloxacin and radezolid are currently in late stage clinical trials.

For more information on the Rib-X mission and the pipeline, please visit the Company website at

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rib-X Granted Key Antibiotic Patent in China
2. Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
3. Rib-X CEO Susan Froshauer, PhD, Honored by The Connecticut Womens Hall of Fame
4. EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
5. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
6. AUDIO from Medialink, Boehringer Ingelheim Pharmaceuticals, Inc. & Pfizer Inc.: Coping with Chronic Obstructive Pulmonary Disease (COPD)
7. The Rossbacher Law Firm, Hagens Berman Sobol Shapiro LLP, Wilentz Goldman & Spitzer, P.A., Reed Smith LLP and Thompson Hine LLP, Announce the Proposed Settlement of a Class Action Lawsuit Concerning Estratest and Solvay Pharmaceuticals, Inc.
8. Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
9. MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
10. DUSA Pharmaceuticals, Inc.(R) Announces Second Quarter Financial Results and Corporate Highlights Conference Call
11. EPIX Pharmaceuticals, Inc. Announces August 25, 2009 for the Auction Sale of Equipment and September 30, 2009 for the Auction Sale of the Intellectual Property
Post Your Comments:
(Date:11/30/2015)... ... 2015 , ... TransPack Volume 6 features 30 customizable transitions created exclusively for ... to wipes with blur & drop shadow options. Utilize the controls in the ... clip to the next with TransPack's easily customizable styles. , TransPack Volume ...
(Date:11/30/2015)... ... November 30, 2015 , ... Workstation ... more than 30 HealthPostures’ dealers located throughout the United States, is OneStop Ergonomics. ... of corporate, industrial, manufacturing and government workers and organizational leaders that are introduced ...
(Date:11/29/2015)... Petersburg, FL (PRWEB) , ... November 30, 2015 ... ... are available today from the new company, Sublime Beauty NATURALS®. All products are ... and natural products, like essential oils, organic facial serums and USDA Certified Organic ...
(Date:11/29/2015)... ... November 29, 2015 , ... Khanna Vision Institute based in Los Angeles, announced ... November 25th 2015. Peer Certification by the Board is done so the public knows ... is first obtained after the completion of three years of training or Residency in ...
(Date:11/29/2015)... ... November 29, 2015 , ... Key Housing, a top-rated corporate housing service for ... featured apartment community: Epic. In showcasing this featured apartment community in San Jose, Key ... rental market to efficiently find housing suitable to their needs by showcasing quality housing. ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 27, 2015  Lannett Company, Inc. (NYSE: ... the acquisition of Kremers Urban Pharmaceuticals Inc. (KU), ... biopharmaceuticals company UCB S.A. (Euronext: UCB). ... acquired KU from UCB for total consideration of ... a customary working capital adjustment, a deduction of ...
(Date:11/26/2015)... november 2015 AAIPharma Services Corp./Cambridge ... investering aan van ten minste $15,8 miljoen ... het mondiale hoofdkantoor in Wilmington, ... in extra kantoorruimte en extra capaciteit voor ... behoeften van de farmaceutische en biotechnologische markten. ...
(Date:11/26/2015)... 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ... is expected to boost the market growth, as 3D bioprinting ... --> 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ...
Breaking Medicine Technology: